|
|
 |
 |
 |
 |
 |
 |
PharmidexHeadquartered within the UK’s Golden Biotech Triangle of Cambridge-Oxford-London, Pharmidex focuses on the prediction and assessment of the ability of potential new medicines to cross the blood-brain barrier (BBB). This adds value by accelerating time to market and improving the probability of success of potential CNS medicines. Pharmidex serves clients worldwide, and in 2005 was awarded the prestigious ‘Service Company of the Year’ by UK’s Department of Trade and Investment. |